Glioblastoma is a particularly aggressive form of brain cancer, and has no effective treatments. Consequently, new therapeutic approaches, such as immunotherapies, are urgently needed to improve patient outcomes. One such therapy is chimeric antigen receptor (CAR) T cell therapy, a form of targeted immunotherapy that involves the modification of a patient’s own T cells to target specific antigens expressed on the tumor cell surface. In this webinar, Dr. Lohitash Karumbaiah and Megan Logan (University of Georgia), use label-free impedance measurements to assess in real-time, the targeting potency of activated human T cells on glioma cell monolayers and demonstrate the value of using an in vitro impedance-based assay to access therapeutic CAR T-cell potency against glioblastoma.
Targeting glioblastoma: Assessing the potency of T cells to kill cancer Lohitash Karumbaiah Megan Logan